Evidence map›Paper›PMID 28623436›Full record

SynthesisStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2017

High-dose-rate brachytherapy as salvage modality for locally recurrent prostate cancer after definitive radiotherapy : A systematic review.

Georgios Chatzikonstantinou, Nikolaos Zamboglou, Claus Rödel, Eleni Zoga, Iosif Strouthos, Saeed Ahmed Butt, Nikolaos Tselis

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Linac-based SBRT as a feasible salvage option for local recurrences in previously irradiated prostate cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020
    Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Georgios ChatzikonstantinouDepartment of Radiotherapy and Oncology, J. W. Goethe University of Frankfurt, Frankfurt am Main, Germany. Georgios.Chatzikonstantinou@kgu.de.ORCID http://orcid.org/0000-0003-3069-2979
Nikolaos ZamboglouDepartment of Radiotherapy and Oncology, J. W. Goethe University of Frankfurt, Frankfurt am Main, Germany.
Claus RödelDepartment of Radiotherapy and Oncology, J. W. Goethe University of Frankfurt, Frankfurt am Main, Germany.
Eleni ZogaDepartment of Radiotherapy and Oncology, Sana Klinikum Offenbach, Offenbach am Main, Germany.
Iosif StrouthosDepartment of Radiotherapy and Oncology, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
Saeed Ahmed ButtDepartment of Medical Physics and Engineering, Sana Klinikum Offenbach, Offenbach am Main, Germany.
Nikolaos TselisDepartment of Radiotherapy and Oncology, J. W. Goethe University of Frankfurt, Frankfurt am Main, Germany.
Goethe University Frankfurt · DESana Klinikum Offenbach · DEUniversity of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo review the current status of interstitial high-dose-rate brachytherapy as a salvage modality (sHDR BRT) for locally recurrent prostate cancer after definitive radiotherapy (RT). MATERIALS AND

methodsA literature search was performed in PubMed using "high-dose-rate, brachytherapy, prostate cancer, salvage" as search terms. In all, 51 search results published between 2000 and 2016 were identified. Data tables were generated and summary descriptions created. The main outcome parameters used were biochemical control (BC) and toxicity scores.

resultsEleven publications reported clinical outcome and toxicity with follow-up ranging from 4-191 months. A variety of dose and fractionation schedules were described, including 19.0 Gy in 2 fractions up to 42.0 Gy in 6 fractions. The 5‑year BC ranged from 18-77%. Late grade 3 genitourinary and gastrointestinal toxicity was 0-32% and 0-5.1%, respectively.

conclusionssHDR BRT appears as safe and effective salvage modality for the reirradiation of locally recurrent prostate cancer after definitive RT.

Indexed as

Re-IrradiationBrachytherapyDose Fractionation, RadiationHumansMaleNeoplasm Recurrence, LocalProstatic NeoplasmsRadiotherapy DosageSalvage TherapyBiochemical failureDose fractionationSalvage therapySide effectsToxicity scores

Identifiers

PMID28623436
OpenAlexW2720739474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.